RESUMO
Conjugates of bacteriochlorin p and chlorin e(6) with cobalt bis(dicarbollide) anion [3,3'-Co(1,2-C(2)B(9)H(11))(2)](-) were synthesized using different synthetic approaches. The boronated bacteriochlorin p was prepared by reaction of bacteriochlorin N-amino cycloimide with, bis(dicarbollide)-based carboxylic acid. The boronated chlorin e(6) conjugates were obtained by both "click reaction" of containing alkyne group chlorine with azide derivative of cobaltacarborane and reaction of chorin-based amines with cyclic oxonium derivative of cobalt bis(dicarbollide).
Assuntos
Compostos de Boro/química , Compostos de Boro/síntese química , Radiossensibilizantes/química , Radiossensibilizantes/síntese química , Terapia por Captura de Nêutron de Boro , Humanos , Estrutura Molecular , Neoplasias/tratamento farmacológico , Neoplasias/radioterapia , Fotoquimioterapia , Porfirinas/síntese química , Porfirinas/químicaRESUMO
Cyclic oxonium derivatives of polyhedral boron hydrides have great potential for modification of various types of tumor seeking biomolecules and are very promising starting materials for synthesis of BNCT (boron neutron capture therapy) agents.
Assuntos
Compostos de Boro/síntese química , Terapia por Captura de Nêutron de Boro/métodos , Neoplasias/radioterapia , Radiossensibilizantes/síntese química , Compostos de Boro/química , Compostos de Boro/uso terapêutico , Desenho de Fármacos , Humanos , Estrutura Molecular , Radiossensibilizantes/química , Radiossensibilizantes/uso terapêuticoRESUMO
A uniform approach to the synthesis of carbohydrate conjugates with polyhedral boron compounds (PBCs) was developed. Oligosaccharide derivatives with an aglycone moiety amino group can be coupled with PBC carboxyl derivatives using N-methyl-N-(4,6-dimethoxy-1,3,5-triazin-2-yl)morpholinium chloride as a coupling agent. Both N- and O-glycosides differing in the conformational mobility around the glycoside bond were shown to be useful as oligosaccharides with a functional group in the aglycone moiety. This allows the application of this approach to the synthesis of PBC conjugates with a wide range of oligosaccharides. For example, not only oligosaccharides obtained by chemical synthesis but also reducing oligosaccharides isolated from natural sources can be transformed into N-glycosides. The approach was tested by the example of conjugation of the carboxyl derivatives of ortho-carborane and dodecaborate anion with lactose as a model oligosaccharide. Lactose, an easily available disaccharide, is a ligand for lectins expressed on the surface of melanoma cells. The approach suggested is the first example of the synthesis of such conjugates that does not require protective groups for the carbohydrate residue. It is especially important for obtaining dodecaborate-carbohydrate conjugates for which the removal of protective groups is often a non-trivial task.
Assuntos
Antineoplásicos/síntese química , Compostos de Boro/síntese química , Lactose/síntese química , Animais , Antineoplásicos/química , Compostos de Boro/química , Terapia por Captura de Nêutron de Boro , Humanos , Lactose/química , Melanoma/radioterapiaRESUMO
The use of polyhedral boron hydrides for cancer treatment is traditionally connected with boron neutron capture therapy. More recently, polyhedral borate anions were proposed as carriers of radionuclide label for targeted radionuclide therapy and diagnostics of cancer. Some metal derivatives of carboranes were found to demonstrate significant antitumor activity themselves. This review is designed to highlight the recent work concerning various fields of potential application of polyhedral boron compounds in anticancer diagnostics and therapy.
Assuntos
Antineoplásicos/uso terapêutico , Compostos de Boro/uso terapêutico , Neoplasias/diagnóstico , Neoplasias/tratamento farmacológico , Animais , Boranos/farmacocinética , Boranos/uso terapêutico , Terapia por Captura de Nêutron de Boro/métodos , Linhagem Celular Tumoral , Humanos , Neoplasias/radioterapiaRESUMO
It has been shown by IR and NMR spectroscopy that cyclic trimeric perfluoro-o-phenylenemercury (o-C6F4-Hg)3 (1) is capable of binding closo-[B10H10]2- and closo-[B12H12]2- anions to form complexes [[(o-C6F4Hg)3](B10-H10)]2- (2), [[(o-C6F4Hg)3]2(B10H10)]2-(3), [[(o-C6F4Hg)3](B12H12)]2- (4), and [[(o-C6F4Hg)3]2(B12H12)]2- (5). According to IR data, the bonding of the [B10H10]2- and [B12H12]2- ions to the macrocycle in these complexes is accomplished through the formation of B-H-Hg bridges. Complexes 2, 3, and 5 have been isolated in analytically pure form and have been characterized by spectroscopic means. X-ray diffraction studies of 3 and 5 have revealed that these compounds have unusual sandwich structures, in which the polyhedral di-anion is located between the planes of two molecules of 1 and is bonded to each of them through two types of B-H-Hg bridges. One type is the simultaneous coordination of a B-H group to all three Hg atoms of the macrocycle. The other type is the coordination of a B-H group to a single Hg atom of the cycle. According to X-ray diffraction data, complex 2 has an analogous but half-sandwich structure. The obtained complexes 2-5 are quite stable; their stability constants in THF/acetone (1:1) at 20 degrees C have been determined as 1.0 x 10(2)Lmol(-1), 2.6 x 10(3)L(2)mol(2), 0.7 x 10(2)Lmol(-1), and 0.98 x 10(3)L(2)mol(-2), respectively.
RESUMO
X-ray diffraction studies reveal the structure of {[(2-C(6)H(5)-1,2-C(2)B(10)H(10)-1-COO)Bu(2)Sn](2)O}(2), 1, to conform to the common motif found for {[(R'COO)R(2)Sn](2)O}(2) compounds. The dimer features a central Bu(2)Sn(2)O(2) unit (two-fold symmetry) with the two Bu(2)Sn groups being linked via bridging oxygen atoms, each of which also carries an exocyclic Bu(2)Sn moiety. The two pairs of exo- and endo-cyclic tin atoms are each linked via an almost symmetrically bridging carboxylate ligand and the two remaining ligands coordinate an exocyclic tin atom only, in the monodentate mode. The in vitro anti-tumour activity of 1, determined against a variety of cell lines, is compared with those of the corresponding 2-methylcarboranylacetate, derivative 2, and with clinically used compounds.